Oligomerix is a biotechnology company focused on developing disease-modifying and treatment therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy dementia to Alzheimer’s disease.
Oligomerix’s lead candidate is a small molecule inhibitor of tau self-association that targets the beginning of the tau aggregation cascade and its progression.
Oligomerix’s platform includes our lead compound (OLX07010) and 2nd generation series of compounds.
August 9, 2022
July 20, 2022